REVIEW PAPER
Prevalence and reasons of loss to follow-up in HIV clinics: a systematic review of current evidence
1
Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
2
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
3
School of Medicine, Islamic Azad University, Tehran, Iran
4
School of Medicine, Iran University of Medical Sciences, Tehran, Iran
5
Department of Health Information Technology, Khalkhal University of Medical Sciences, Khalkhal, Iran
6
School of Public Health, Walailak University, Nakhon Si Thammarat, Thailand
Submission date: 2021-07-31
Final revision date: 2021-08-18
Acceptance date: 2021-08-26
Publication date: 2022-07-05
HIV & AIDS Review 2022;21(3):179-190
KEYWORDS
TOPICS
ABSTRACT
Introduction: Loss to follow-up (LTFU) slows the progress in reaching the goals of human immunodeficiency virus (HIV) prevention and treatment. Therefore, it is important to understand the causes behind this phenomena. Herein, we aimed to systematically review the prevalence of LTFU among people living with HIV and the reasons behind this event.
Material and methods: A systematic search was conducted with key words applied in online databases, including PubMed, Web of Science, Scopus, UpToDate, and Science Direct, from January 2015 to March 2021. Most relevant papers were retrieved and screened in two phases against inclusion criteria, based on their title/abstract and their full texts, and eligible records were included in the review.
Results: In this systematic review, 54 studies were included. Unfavorable socio-demographic and supportive status, distance to facility, age, gender, challenges related to antiretroviral therapy initiation and its’ side effects, and CD4+ counts were among the most common reasons cited for LTFU in HIV clinics.
Conclusions: LTFU remains a major factor halting the progress in the prevention and treatment of HIV. Great efforts are still needed to address this issue, especially in populations and regions with higher LTFU incidence. Accessibility of receiving care should be increased to encourage patients to continue their treatments. Upcoming follow-up studies are needed to re-evaluate the progress and to report future challenges and limitations.
Material and methods: A systematic search was conducted with key words applied in online databases, including PubMed, Web of Science, Scopus, UpToDate, and Science Direct, from January 2015 to March 2021. Most relevant papers were retrieved and screened in two phases against inclusion criteria, based on their title/abstract and their full texts, and eligible records were included in the review.
Results: In this systematic review, 54 studies were included. Unfavorable socio-demographic and supportive status, distance to facility, age, gender, challenges related to antiretroviral therapy initiation and its’ side effects, and CD4+ counts were among the most common reasons cited for LTFU in HIV clinics.
Conclusions: LTFU remains a major factor halting the progress in the prevention and treatment of HIV. Great efforts are still needed to address this issue, especially in populations and regions with higher LTFU incidence. Accessibility of receiving care should be increased to encourage patients to continue their treatments. Upcoming follow-up studies are needed to re-evaluate the progress and to report future challenges and limitations.
REFERENCES (89)
1.
UNAIDS. Global HIV & AIDS statistics – fact sheet 2020. Available from: https://www.unaids.org/en/reso....
2.
de Olalla PG, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylà JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30: 105-110.
3.
Banerjee T, Pensi T, Banerjee D, Grover G. Impact of HAART on survival, weight gain and resting energy expenditure in HIV-1-infected children in India. Ann Trop Paediatr 2010; 30: 27-37.
4.
Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the EuroSIDA Study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr 1999; 22: 369-378.
5.
Fleishman JA, Yehia BR, Moore RD, Korthuis PT, Gebo KA; HIV Research Network. Establishment, retention, and loss to follow-up in outpatient HIV care. J Acquir Immune Defic Syndr 2012; 60: 249-259.
6.
Centers for Disease Control and Prevention (CDC). Late HIV testing – 34 states, 1996-2005. MMWR Morb Mortal Wkly Rep 2009; 58: 661-665.
7.
Mugavero MJ, Lin HY, Allison JJ, et al. Failure to establish HIV care: characterizing the “no show” phenomenon. Clin Infect Dis 2007; 45: 127-130.
8.
UNAIDS. 90-90-90 – An ambitious treatment target to help end the AIDS epidemic 2017, January 1. Available from: https://www.unaids.org/en/reso....
9.
Ochieng-Ooko V, Ochieng D, Sidle JE, et al. Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bull World Health Organ 2010; 88: 681-688.
10.
Micek MA, Gimbel-Sherr K, Baptista AJ, et al. Loss to follow-up of adults in public HIV care systems in Mozambique: identifying obstacles to treatment. J Acquir Immune Defic Syndr 2009; 52: 397-405.
11.
Chi BH, Yiannoutsos CT, Westfall AO, et al. Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med 2011; 8: e1001111.
12.
Ndiaye B, Ould-Kaci K, Salleron J, et al. Characteristics of and outcomes in HIV-infected patients who return to care after loss to follow-up. AIDS 2009; 23: 1786-1789.
13.
Horstmann E, Brown J, Islam F, Buck J, Agins BD. Retaining HIV-infected patients in care: Where are we? Where do we go from here? Clin Infect Dis 2010; 50: 752-761.
14.
Mugavero MJ. Improving engagement in HIV care: what can we do? Top HIV Med 2008; 16: 156-161.
15.
Ulett KB, Willig JH, Lin HY, et al. The therapeutic implications of timely linkage and early retention in HIV care. AIDS Patient Care STDS 2009; 23: 41-49.
16.
Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131: 81-87.
17.
Berg M, Safren S, Mimiaga M, Grasso C, Boswell S, Mayer KH. Non¬adherence to medical appointments is associated with increased plasma HIV RNA and decreased CD4 cell counts in a community-based HIV primary care clinic. AIDS Care 2005; 17: 902-907.
18.
Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003; 37: 1112-1118.
19.
Giordano TP, White AC, Sajja P, et al. Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr 2003; 32: 399-405.
20.
Mugavero MJ, Lin HY, Willig JH, et al. Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis 2009; 48: 248-256.
21.
Metsch LR, Pereyra M, Messinger S, et al. HIV transmission risk behaviors among HIV-infected persons who are successfully linked to care. Clin Infect Dis 2008; 47: 577-584.
22.
Arici C, Ripamonti D, Maggiolo F, et al. Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clin Trials 2002; 3: 52-57.
23.
Gardner LI, Metsch LR, Anderson-Mahoney P, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS 2005; 19: 423-431.
24.
Adelekan B, Andrew N, Nta I, et al. Social barriers in accessing care by clients who returned to HIV care after transient loss to follow-up. AIDS Res Ther 2019; 16: 17.
25.
Lubega M, Musenze IA, Joshua G, et al. Sex inequality, high transport costs, and exposed clinic location: reasons for loss to follow-up of clients under prevention of mother-to-child HIV transmission in eastern Uganda – a qualitative study. Patient Prefer Adherence 2013; 7: 447-454.
26.
Fayorsey RN, Saito S, Carter RJ, et al. Decentralization of pediatric HIV care and treatment in five sub-Saharan African countries. J Acquir Immune Def Syndr 2013; 62: e124-e130.
27.
Kigen HT, Galgalo T, Githuku J, et al. Predictors of loss to follow up among HIV-exposed children within the prevention of mother to child transmission cascade, Kericho County, Kenya, 2016. Pan Afr Med J 2018; 30: 178.
28.
Anderegg N, Johnson LF, Zaniewski E, et al. All-cause mortality in HIV-positive adults starting combination antiretroviral therapy: correcting for loss to follow-up. AIDS 2017; 31 Suppl 1: S31-S40.
29.
Ojwang VO, Penner J, Blat C, Agot K, Bukusi EA, Cohen CR. Loss to follow-up among youth accessing outpatient HIV care and treatment services in Kisumu, Kenya. AIDS Care 2016; 28: 500-507.
30.
Saumu WM, Maleche-Obimbo E, Irimu G, Kumar R, Gichuhi C, Karau B. Predictors of loss to follow-up among children attending HIV clinic in a hospital in rural Kenya. Pan Afr Med J 2019; 32: 216.
31.
Wahome EW, Graham SM, Thiong’o AN, et al. Risk factors for loss to follow-up among at-risk HIV negative men who have sex with men participating in a research cohort with access to pre-exposure prophylaxis in coastal Kenya. J Int AIDS Soc 2020; 23 Suppl 6: e25593.
32.
Wekesa P, McLigeyo A, Owuor K, Mwangi J, Nganga E, Masamaro K. Factors associated with 36-month loss to follow-up and mortality outcomes among HIV-infected adults on antiretroviral therapy in Central Kenya. BMC Public Health 2020; 20: 328.
33.
Matsena Zingoni Z, Chirwa T, Todd J, Musenge E. Competing risk of mortality on loss to follow-up outcome among patients with HIV on ART: a retrospective cohort study from the Zimbabwe national ART programme. BMJ Open 2020; 10: e036136.
34.
Chandiwana N, Sawry S, Chersich M, Kachingwe E, Makhathini B, Fairlie L. High loss to follow-up of children on antiretroviral treatment in a primary care HIV clinic in Johannesburg, South Africa. Medicine (Baltimore) 2018; 97: e10901.
35.
Mulongeni P, Hermans S, Caldwell J, Bekker LG, Wood R, Kaplan R. HIV prevalence and determinants of loss-to-follow-up in adolescents and young adults with tuberculosis in Cape Town. PLoS One 2019; 14: e0210937.
36.
Onoya D, Sineke T, Brennan AT, Long L, Fox MP. Timing of pregnancy, postpartum risk of virologic failure and loss to follow-up among HIV-positive women. AIDS 2017; 31: 1593-1602.
37.
Papavarnavas NS, Manning K, Conrad F, Govender M, Maartens G. Factors associated with loss to follow-up after occupational HIV exposure in Cape Town, South Africa: a retrospective cohort study. AIDS Res Ther 2017; 14: 23.
38.
Yende-Zuma N, Naidoo K. The effect of timing of initiation of anti¬retroviral therapy on loss to follow-up in HIV-tuberculosis coinfected patients in South Africa: an open-label, randomized, controlled trial. J Acquir Immune Def Syndr 2016; 72: 430-436.
39.
Gwynn RC, Fawzy A, Viho I, Wu Y, Abrams EJ, Nash D. Risk factors for loss to follow-up prior to ART initiation among patients enrolling in HIV care with CD4+ cell count ≥200 cells/μL in the multi-country MTCT-Plus Initiative. BMC Health Serv Res 2015; 15: 247.
40.
Hickey MD, Omollo D, Salmen CR, et al. Movement between facilities for HIV care among a mobile population in Kenya: transfer, loss to follow-up, and reengagement. AIDS Care 2016; 28: 1386-1393.
41.
Joseph Davey D, Kehoe K, Serrao C, et al. Same-day antiretroviral therapy is associated with increased loss to follow-up in South African public health facilities: a prospective cohort study of patients diagnosed with HIV. J Int AIDS Soc 2020; 23: e25529.
42.
McCormick NM, Li N, Sando D, et al. Implementation and operational research: risk factors of loss to follow-up among HIV-positive pediatric patients in Dar es Salaam, Tanzania. J Acquir Immune Def Syndr 2015; 70: e73-e83.
43.
Agwu AL, Lee L, Fleishman JA, et al. Aging and loss to follow-up among youth living with human immunodeficiency virus in the HIV Research Network. J Adolesc Health 2015; 56: 345-351.
44.
Assemie MA, Muchie KF, Ayele TA. Incidence and predictors of loss to follow up among HIV-infected adults at Pawi General Hospital, northwest Ethiopia: competing risk regression model. BMC Res Notes 2018; 11: 287.
45.
Birhanu MY, Leshargie CT, Alebel A, et al. Incidence and predictors of loss to follow-up among HIV-positive adults in northwest Ethiopia: a retrospective cohort study. Trop Med Health 2020; 48: 78.
46.
Fisiha Kassa S, Zemene Worku W, Atalell KA, Agegnehu CD. Incidence of loss to follow-up and its predictors among children with HIV on antiretroviral therapy at the University of Gondar Comprehensive Specialized Referral Hospital: a retrospective data analysis. HIV/AIDS 2020; 12: 525-533.
47.
Mekonnen N, Abdulkadir M, Shumetie E, Baraki AG, Yenit MK. Incidence and predictors of loss to follow-up among HIV infected adults after initiation of first line anti-retroviral therapy at University of Gondar comprehensive specialized Hospital Northwest Ethiopia, 2018: retrospective follow up study. BMC Res Notes 2019; 12: 111.
48.
Teshale AB, Tsegaye AT, Wolde HF. Incidence and predictors of loss to follow up among adult HIV patients on antiretroviral therapy in University of Gondar Comprehensive Specialized Hospital: a competing risk regression modeling. PLoS One 2020; 15: e0227473.
49.
Agolory SG, Auld AF, Odafe S, et al. High rates of loss to follow-up during the first year of pre-antiretroviral therapy for HIV patients at sites providing pre-ART care in Nigeria, 2004-2012. PLoS One 2017; 12: e0183823.
50.
Aliyu MH, Blevins M, Megazzini KM, et al. Pregnant women with HIV in rural Nigeria have higher rates of antiretroviral treatment initiation, but similar loss to follow-up as non-pregnant women and men. Int Health 2015; 7: 405-411.
51.
Eguzo KN, Lawal AK, Umezurike CC, Eseigbe CE. Predictors of loss to follow-up among HIV-infected patients in a rural south-eastern Nigeria hospital: a 5-year retrospective cohort study. Ann Med Health Sci Res 2015; 5: 373-378.
52.
Mehta K, Kumar AMV, Chawla S, et al. ‘M-TRACK’ (mobile phone reminders and electronic tracking tool) cuts the risk of pre-treatment loss to follow-up by 80% among people living with HIV under programme settings: a mixed-methods study from Gujarat, India. Glob Health Action 2018; 11: 1438239.
53.
Mehta KG, Baxi R, Patel S, Parmar M. Drug adherence rate and loss to follow-up among people living with HIV/AIDS attending an ART Centre in a Tertiary Government Hospital in Western India. J Fam Med Primary Care 2016; 5: 266-269.
54.
Devi NP, Kumar AMV, Chinnakali P, et al. Loss to follow-up among children in pre-ART care under the National AIDS Programme, Tamil Nadu, South India. Public Health Action 2017; 7: 90-94.
55.
Nimkar S, Valvi C, Kadam D, et al. Loss to follow-up and mortality among HIV-infected adolescents receiving antiretroviral therapy in Pune, India. HIV Med 2018; 19: 395-402.
56.
Gu D, Mao Y, Tang Z, et al. Loss to follow-up from HIV screening to ART initiation in rural China. PLoS One 2016; 11: e0164346.
57.
Su Y, Ding G, Reilly KH, et al. Loss to follow-up and HIV incidence in female sex workers in Kaiyuan, Yunnan Province China: a nine year longitudinal study. BMC Infect Dis 2016; 16: 526.
58.
Tang W, Huan X, Zhang Y, et al. Factors associated with loss-to-follow-up during behavioral interventions and HIV testing cohort among men who have sex with men in Nanjing, China. PLoS One 2015; 10: e115691.
59.
Bilinski A, Birru E, Peckarsky M, et al. Distance to care, enrollment and loss to follow-up of HIV patients during decentralization of antiretroviral therapy in Neno District, Malawi: a retrospective cohort study. PLoS One 2017; 12: e0185699.
60.
Mpinganjira S, Tchereni T, Gunda A, Mwapasa V. Factors associated with loss-to-follow-up of HIV-positive mothers and their infants enrolled in HIV care clinic: a qualitative study. BMC Public Health 2020; 20: 298.
61.
Tweya H, Oboho IK, Gugsa ST, et al. Loss to follow-up before and after initiation of antiretroviral therapy in HIV facilities in Lilongwe, Malawi. PLoS One 2018; 13: e0188488.
62.
Kiwanuka J, Mukulu Waila J, Muhindo Kahungu M, Kitonsa J, Kiwanuka N. Determinants of loss to follow-up among HIV positive patients receiving antiretroviral therapy in a test and treat setting: a retrospective cohort study in Masaka, Uganda. PLoS One 2020; 15: e0217606.
63.
Ankunda R, Cumber SN, Atuhaire C, et al. Loss to follow-up and associated maternal factors among HIV-exposed infants at the Mbarara Regional Referral Hospital, Uganda: a retrospective study. BMC Infect Dis 2020; 20: 235.
64.
Opio D, Semitala FC, Kakeeto A, et al. Loss to follow-up and associated factors among adult people living with HIV at public health facilities in Wakiso district, Uganda: a retrospective cohort study. BMC Health Serv Res 2019; 19: 628.
65.
Kalinjuma AV, Glass TR, Weisser M, et al. Prospective assessment of loss to follow-up: incidence and associated factors in a cohort of HIV-positive adults in rural Tanzania. J Int AIDS Soc 2020; 23: e25460.
66.
Siril HN, Kaaya SF, Smith Fawzi MK, et al. CLINICAL outcomes and loss to follow-up among people living with HIV participating in the NAMWEZA intervention in Dar es Salaam, Tanzania: a prospective cohort study. AIDS Res Ther 2017; 14: 18.
67.
Lain MG, Chicumbe S, de Araujo AR, et al. Correlates of loss to follow-up and missed diagnosis among HIV-exposed infants throughout the breastfeeding period in southern Mozambique. PLoS One 2020; 15: e0237993.
68.
Blevins M, José E, Bilhete FR, et al. Two-year death and loss to follow-up outcomes by source of referral to HIV care for HIV-infected patients initiating antiretroviral therapy in rural Mozambique. AIDS Res Hum Retroviruses 2015; 31: 198-207.
69.
Grangeiro A, Nascimento M, Zucchi EM, et al. Nonoccupational post-exposure prophylaxis for HIV after sexual intercourse among women in Brazil: risk profiles and predictors of loss to follow-up. Medicine (Baltimore) 2019; 98: e17071.
70.
Silva AP, Greco M, Fausto MA, Carneiro M. Loss to follow-up in a cohort of HIV-negative men who have sex with men: Project Horizonte. Rev Saude Publica 2017; 51: 60.
71.
Jerene D, Abebe W, Taye K, Ruff A, Hallstrom I. Adolescents living with HIV are at higher risk of death and loss to follow up from care: analysis of cohort data from eight health facilities in Ethiopia. PLoS One 2019; 14: e0223655.
72.
Jose S, Delpech V, Howarth A, et al. A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study. Lancet HIV 2018; 5: e301-e308.
73.
Kyaw KWY, Oo MM, Kyaw NTT, et al. Low mother-to-child HIV transmission rate but high loss-to-follow-up among mothers and babies in Mandalay, Myanmar; a cohort study. PLoS One 2017; 12: e0184426.
74.
Bernard C, Balestre E, Coffie PA, et al. Aging with HIV: what effect on mortality and loss to follow-up in the course of antiretroviral therapy? The IeDEA West Africa Cohort Collaboration. HIV/AIDS (Auckl) 2018; 10: 239-252.
75.
Steiniche D, Jespersen S, Medina C, Sanha FC, Wejse C, Hønge BL. Excessive mortality and loss to follow-up among HIV-infected children in Guinea-Bissau, West Africa: a retrospective follow-up study. Trop Med Int Health 2018; 23: 1148-1156.
76.
Akilimali PZ, Musumari PM, Kashala-Abotnes E, et al. Disclosure of HIV status and its impact on the loss in the follow-up of HIV-infected patients on potent anti-retroviral therapy programs in a (post-) conflict setting: a retrospective cohort study from Goma, Democratic Republic of Congo. PLoS One 2017; 12: e0171407.
77.
Baldé A, Lièvre L, Maiga AI, et al. Risk factors for loss to follow-up, transfer or death among people living with HIV on their first anti-retroviral therapy regimen in Mali. HIV Med 2019; 20: 47-53.
78.
De La Mata NL, Ly PS, Nguyen KV, et al. Loss to follow-up trends in HIV-positive patients receiving antiretroviral treatment in Asia from 2003 to 2013. J Acquir Immune Def Syndr 2017; 74: 555-562.
79.
Sidze LK, Faye A, Tetang SN, et al. Different factors associated with loss to follow-up of infants born to HIV-infected or uninfected mothers: observations from the ANRS 12140-PEDIACAM study in Cameroon. BMC Public Health 2015; 15: 228.
80.
Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for Economic Evaluation of Health Care Programmes. New York: Oxford Medical Publication; 2005.
81.
Granich R, Gupta S, Hall I, Aberle-Grasse J, Hader S, Mermin J. Status and methodology of publicly available national HIV care continua and 90-90-90 targets: a systematic review. PLoS Med 2017; 14: e1002253.
82.
McNairy ML, Joseph P, Unterbrink M, et al. Outcomes after anti¬retroviral therapy during the expansion of HIV services in Haiti. PLoS One 2017; 12: e0175521.
83.
Kawilapat S, Salvadori N, Ngo-Giang-Huong N, et al. Incidence and risk factors of loss to follow-up among HIV-infected children in an antiretroviral treatment program. PLoS One 2019; 14: e0222082.
84.
SeyedAlinaghi S, Taj L, Mazaheri-Tehrani E, et al. HIV in Iran: onset, responses, and future directions. AIDS 2021; 35: 529-542.
85.
Farhoudi B, Seyedalinaghi S, Jafarinasab M, et al. Barriers to anti¬retroviral therapy adherence in one of the prisons in Iran. Infect Disord Drug Targets 2020; 20: 848-853.
86.
Paydary K, Ekhtiari H, Noori M, Rad MV, Hajiabdolbaghi M, Seyed¬Alinaghi S. Evaluation of the association between Addiction Severity Index and depression with adherence to anti-retroviral therapy among HIV infected patients. Infect Disord Drug Targets 2015; 15: 177-183.
87.
Khalili H, Rohani R, Seyedalinaghi S, Hajiabdolbaghi M, Dashti-Khavidaki S, Talasaz AH. Adherence to antiretroviral therapy among Iranian HIV/AIDS patients. Curr Clin Pharmacol 2012; 7: 111-115.
88.
Emamzadeh-Fard S, Fard SE, SeyedAlinaghi S, Paydary K. Adherence to anti-retroviral therapy and its determinants in HIV/AIDS patients: a review. Infect Disord Drug Targets 2012; 12: 346-356.
89.
McCormick NM, Nan L, Sando D, et al. Risk factors of loss to follow up among HIV positive pediatric patients in Dar es Salaam, Tanzania. J Acquir Immune Def Syndr 2015; 70: e73.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
